Rajeev Saggar Sells 5,327 Shares of Liquidia Technologies, Inc. (NASDAQ:LQDA) Stock

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) insider Rajeev Saggar sold 5,327 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $76,069.56. Following the completion of the transaction, the insider directly owned 271,413 shares in the company, valued at approximately $3,875,777.64. This trade represents a 1.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Rajeev Saggar also recently made the following trade(s):

• On Monday, April 21st, Rajeev Saggar sold 2,450 shares of Liquidia Technologies stock. The shares were sold at an average price of $13.67, for a total value of $33,491.50.

Liquidia Technologies Stock Down 0.6%

Shares of LQDA traded down $0.09 during midday trading on Wednesday, hitting $14.43. The stock had a trading volume of 501,684 shares, compared to its average volume of 1,302,642. The company has a 50 day simple moving average of $14.92 and a two-hundred day simple moving average of $14.46. Liquidia Technologies, Inc. has a twelve month low of $8.26 and a twelve month high of $19.41. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -9.14 and a beta of -0.01. The company has a debt-to-equity ratio of 2.08, a current ratio of 2.93 and a quick ratio of 2.91.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia Technologies had a negative net margin of 903.80% and a negative return on equity of 177.91%. The firm had revenue of $3.12 million during the quarter, compared to analyst estimates of $3.23 million. On average, analysts anticipate that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Wall Street Analyst Weigh In

LQDA has been the topic of a number of analyst reports. Raymond James Financial increased their price target on Liquidia Technologies from $27.00 to $29.00 and gave the company a "strong-buy" rating in a research note on Friday, May 9th. Scotiabank increased their price target on Liquidia Technologies from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research note on Wednesday, May 28th. Bank of America dropped their price objective on Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Wednesday, June 11th. Wells Fargo & Company raised their price objective on Liquidia Technologies from $23.00 to $25.00 and gave the stock an "overweight" rating in a research note on Thursday, June 12th. Finally, Wall Street Zen raised Liquidia Technologies from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $26.89.

Institutional Trading of Liquidia Technologies

Hedge funds and other institutional investors have recently modified their holdings of the company. Cetera Investment Advisers raised its stake in shares of Liquidia Technologies by 4.3% in the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock valued at $367,000 after purchasing an additional 1,277 shares during the period. Deutsche Bank AG raised its stake in shares of Liquidia Technologies by 53.4% in the 4th quarter. Deutsche Bank AG now owns 51,075 shares of the company's stock valued at $601,000 after purchasing an additional 17,790 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Liquidia Technologies in the 4th quarter valued at about $218,000. Millennium Management LLC bought a new position in shares of Liquidia Technologies in the 4th quarter valued at about $526,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Liquidia Technologies by 9.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company's stock valued at $5,040,000 after acquiring an additional 38,313 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).